OliX Pharmaceuticals

OliX Pharmaceuticals develops medicines that work by silencing the specific genes responsible for hard-to-treat diseases, a technique known as RNA interference (RNAi).

It focuses on a proprietary molecule structure called cp-asiRNA, which is designed to block disease-causing proteins more precisely and with fewer unwanted side effects than earlier approaches. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company operates primarily as a technology-licensing business, transferring its RNAi platform and drug-candidate rights to domestic and international pharmaceutical companies in exchange for fees.